Lyell Immunopharma (LYEL)

• Market cap: $365M
• 1 day: -3.96%
• 5 days: 1.29%
• 1 month: -4.55%
• 3 months: 59%
• 6 months: 108.47%
• Year to date: 33.49%
• 1 year: -22.43%
• 5 years: -94.9%
• 10 years: -94.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300